| Name
|
Orphanin FQ/Nociceptin, Human, Mouse, Ox, Rat
|
| Other Name
|
Orphanin FQ,human, mouse, ox, rat
|
| Sequence (Single letter abbreviations)
|
FGGFTGARKSARKLANQ
|
| Sequence（Three letter abbreviations）
|
{PHE}{GLY}{GLY}{PHE}{THR}{GLY}{ALA}{ARG}{LYS}{SER}{ALA}{ARG}{LYS}{LEU}{ALA}{ASN}{GLN}
|
| Basic description
|
Orphanin FQ was identified and purified from porcine brain tissue as a ligand for an orphan heterotrimeric GTP-inding protein (G protein)-coupled receptor (LC132) that is similar in sequence to opioid receptors. Orphanin FQ has a primary structure reminiscent of that of opioid peptides. Nanomolar concentrations of orphanin FQ have inhibited forskolin-stimulated adenylyl cyclase activity in cells transfected with LC132. This inhibitory activity was not affected by the addition of opioid ligands, nor did the peptide activate opioid receptors. Orphanin FQ bound to its receptor in a saturable manner and with affinity.
|
| Solubility
|
The peptide is soluble in water. The contents of this vial have been accurately determined. Both the stopper and the vial have been siliconized. Do not attempt to weigh out a smaller portion of the contents.
|
| The molecular weight
|
1809.050
|
| Chemical formula
|
C79H129N27O22
|
| The purity
|
> 95%
|
| Storage conditions
|
Storage at -20°C. Keep tightly closed.
|
| Annotation
|
In conscious rats intravenous infusion of orphanin FQ produced a profound increase in urine flow rate and decrease in urinary sodium excretion.
|
| Documents
|
|
| Figures
|
|
| Reference
|
Chung S, et al. Endogenous orphanin FQ / nociceptin is involved in the development of morphine tolerance. J. Pharmacol. Exp. Ther. Apr 2006.(Epub ahead of print).
Marti M, et al. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J. Neursci. Oct 2005; 25(42): 9591-9601.
|
Orphanin FQ/Nociceptin, Human, Mouse, Ox, Rat
